REPORT FROM THE 25^th CONGRESS OF THE ECTRIMS – Dusseldorf, Germany, September 9-12, 2009  Teriflunomide is an immunosuppressant currently being tested in four large phase III trials in clinically isolated syndrome (estimated enrollment 780), MS with relapses (TEMSO trial, estimated n=1080), relapsing-remitting MS (planned n=1110) and versus beta-interferon-1a in RRMS (TENERE trial, estimated n=300).  The drug is the active metabolite of leflunomide that is used in the treatment of rheumatoid arthritis.
Read More

REPORT FROM THE 25^th CONGRESS OF THE ECTRIMS – Dusseldorf, Germany, September 9-12, 2009  In 2008, the MS Study Group of the Italian Neurological Society reported that one-third of children/adolescents with MS demonstrated cognitive impairments (Amato et al. Neurology 2008; 70: 1891-1897).
Read More

REPORT FROM THE 25^th CONGRESS OF THE ECTRIMS – Dusseldorf, Germany, September 9-12, 2009  Alemtuzumab (Campath 1H) is a monoclonal antibody that targets CD52, a cell surface molecule found on thymocytes, lymphocytes, monocytes and eosinophils. Early data suggested that the agent could reduce disability (Coles et al. J Neurol 2006; 253: 98-108), which led to the phase II CAMMS223 trial comparing alemtuzumab with beta-interferon-1a (CAMMS223 Investigators. N Engl J Med 2008; 359: 1786-1801). 
Read More

 REPORT FROM THE 25^th CONGRESS OF THE ECTRIMS – Dusseldorf, Germany, September 9-12, 2009 – Three studies at the 25^th ECTRIMS congress presented new data on vitamin D and multiple sclerosis.

Read More